Sugi Predict

Sugi Predict / Compounds / SCHEMBL25949124

SCHEMBL25949124

SCHEMBL25949124

C=C1CCC(n2c(C)nc3cccc(C(C)C)c3c2=O)C(=O)N1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 14/20 0.59
▸ CRBN Q96SW2 14/20 0.59
▸ IKZF3 Q9UKT9 2/20 0.59
▸ TNF P01375 1/20 0.59
▸ IL1B P01584 1/20 0.59
▸ GAA P10253 3/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ KDM4E B2RXH2 4/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ CYP1A2 P05177 4/20 0.33
▸ GLA P06280 4/20 0.33
▸ CYP3A4 P08684 4/20 0.33
▸ CYP2C9 P11712 4/20 0.33
▸ HPGD P15428 4/20 0.33
▸ CASP1 P29466 4/20 0.33
▸ HSD17B10 Q99714 4/20 0.33
▸ MAPK1 P28482 3/20 0.33
▸ CASP7 P55210 3/20 0.33
▸ TSHR P16473 2/20 0.33
▸ ELANE P08246 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26725329 1.00 DDB1 (0.59) DDB1CRBNIKZF3TNFIL1B
SCHEMBL26725330 1.00 DDB1 (0.59) DDB1CRBNIKZF3TNFIL1B
SCHEMBL20932983 0.89 DDB1 (0.73) DDB1CRBNIKZF3TNFIL1B
SCHEMBL23945504 0.89 DDB1 (0.73) DDB1CRBNIKZF3TNFIL1B
SCHEMBL23806413 0.89 DDB1 (0.73) DDB1CRBNIKZF3TNFIL1B
SCHEMBL12638348 0.87 DDB1 (0.63) DDB1CRBNIKZF3TNFIL1B
SCHEMBL16768175 0.87 DDB1 (0.63) DDB1CRBNIKZF3TNFIL1B
SCHEMBL15745529 0.85 CRBN (0.80) DDB1CRBNIKZF3TNFIL1B
SCHEMBL25477252 0.85 DDB1 (0.56) DDB1CRBNIKZF3TNFIL1B
SCHEMBL25565711 0.85 DDB1 (0.56) DDB1CRBNIKZF3TNFIL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-11702402-B2 Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IKZF3 135/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IKZF3 135/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IKZF3 135/4885
US-11702402-B2 Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof CRBN, PSME3, PSMB10 DDB1 987/4885CRBN 1/4885IKZF3 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.